Showing 40,261 - 40,280 results of 104,171 for search '(( e point decrease ) OR ( 5 ((((mean decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.37s Refine Results
  1. 40261

    Table_1_Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia random... by Xiaomei Leng (614420)

    Published 2023
    “…We aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose (SAD) of WBP216 in patients with rheumatoid arthritis (RA).…”
  2. 40262
  3. 40263

    Supplementary Material for: Clusters of Severe Eosinophilic Asthma in a Korean Asthma Cohort by Lee J.-H. (3189423)

    Published 2021
    “…<b><i>Objectives:</i></b> We aimed to describe the characteristics of SEA and identify its patient subgroups. …”
  4. 40264

    Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model by Cristina Mazzaccara (169715)

    Published 2013
    “…</p><p>Results</p><p>Warfarin dose variability was influenced, in decreasing order, by VKORC1-1639 G>A (29.7%), CYP2C9*3 (11.8%), age (8.5%), CYP2C9*2 (3.5%), gender (2.0%) and lastly CYP4F2*3 (1.7%); VKORC1 1173 C>T and VKORC1 3730 G>A exerted a slight effect (<1% each). …”
  5. 40265
  6. 40266
  7. 40267
  8. 40268
  9. 40269

    Ptf1a triggers GABAergic neuronal cell fates in the retina-1 by Jean-Philippe Dullin (39281)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "Ptf1a triggers GABAergic neuronal cell fates in the retina"</p><p>http://www.biomedcentral.com/1471-213X/7/110</p><p>BMC Developmental Biology 2007;7():110-110.…”
  10. 40270
  11. 40271
  12. 40272

    A real-time speech understanding test (Buchholz et al., 2022) by Joerg M. Buchholz (14124761)

    Published 2022
    “…We tested 63 younger adults, using five semantic categories (family, media, season, temperature, and travel) at three noise levels (in quiet, 0 dB, and −5 dB signal-to-noise ratio [SNR]). …”
  13. 40273
  14. 40274

    Table_1_A low-protein maternal diet during gestation affects the expression of key pancreatic β-cell genes and the methylation status of the regulatory region of the MafA gene in t... by Tonantzin C. Sosa-Larios (14781604)

    Published 2023
    “…A decrease in the DNA methylation levels was found in the 5' flanking region between nucleotides −8118 to −7750 of the MafA regulatory region in restricted offspring compared with control pancreatic islets. …”
  15. 40275

    A Chromosome-Level Reference Genome Assembly and Evolution of Dongxiang Wild Rice by chunxiu shen (8944760)

    Published 2022
    “…A total of 58.41 Gb clean data were de novo assembled into 231 contigs with the total length of 413.46 Mb and N50 length of 5.18 Mb. …”
  16. 40276

    A nested case-control study of 277 prediagnostic serum cytokines and glioma by Judith Schwartzbaum (793406)

    Published 2017
    “…We have documented prediagnostic changes in serum cytokine levels that may reflect the presence of a preclinical tumor.…”
  17. 40277

    A review of grass species yields and growth rates in Northland, New Zealand by Carmen S. P. Teixeira (9938331)

    Published 2024
    “…The medium-term prospect suggests an urgent need to improve research into management of cocksfoot and tall fescue-based pastures to provide viable alternatives to overcome the decreasing persistence of perennial ryegrass.</p> <p><a href="https://www.tandfonline.com/pb-assets/tandf/Migrated/Video_Transcript_TNZA_2351614.pdf" target="_blank">Read the transcript</a></p> <p><a href="https://vimeo.com/964566516" target="_blank">Watch the video on Vimeo</a></p> <p>© 2024 The Author(s). …”
  18. 40278
  19. 40279
  20. 40280

    Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-co... by Tadao Akizawa (316095)

    Published 2018
    “…</p><p>Results</p><p>In total, 152 HDSHPT were randomized. The mean ± standard deviation (median, interquartile range) of percent changes in iPTH from baseline to end of treatment were −8.40±25.43% (−12.16, 39.60), −10.56±22.86% (−14.24, 27.85), and −20.16±34.23% (−23.83, 39.05) in the evocalcet 0.5, 1, and 2 mg/day groups and 5.44±25.85% (3.52, 35.39) and −25.86±27.76% (−29.79, 34.15) in the placebo and cinacalcet groups, respectively. …”